SIRPA and neoplasm: These findings provide compelling evidence that therapeutic strategies aimed at disrupting the CD47/αvβ3 axis on malignant cells may effectively curtail tumor progression while preserving the CD47–SIRPα immune checkpoint that governs erythrocyte clearance and prevents immunotoxicity.